Linkin

Bio

Managing Director for boutique economic consulting firm EPG, specialising in economic analysis, strategic communications and market entry assistance with India, with offices in London, Bangalore and East Africa.

He was additionally, until August 2017, UK Director for the Federation of Indian Chambers of Commerce and Industry (FICCI), the premier and largest industry body in India. He is also the co-founder of a tech start-up in the CSR space. Previously he worked in Economic Consulting at FTI Consulting and Deloitte in London and Abu Dhabi, with a focus on public policy and arbitration. He was Chairman for a not-for-profit membership organisation with several thousand members for three years.

He studied Economics at Warwick University, where he was awarded the Prize for Excellence, and LMU University of Munich. His dissertation won a prize at an international economics conference at Georgetown University, Washington DC. He has published academic research on behavioural economics and social impact and is a regular commentator on public policy and India across print, TV and online media, featured on BBC News, CBC, CNBC, CNN, NDTV, South China Morning Post and Huffington Post.

Sessions

Linkin

Bio

Sessions

Linkin

Bio

Dr. Stephen Minger research has been at the forefront of human stem cell research. His group was the first to deposit a human ES cell line into the UK Stem Cell Bank and first to pursue Somatic Cell Nuclear Transfer (SCNT) to generate “hybrid human embryos” for research. Besides research, Stephen has been actively involved with the UK government helping legislate the first Human Embryo Bill in 2009 and being the Stem Cell Expert and Member of the UK Gene Therapy Advisory Committee (GTAC) at the Department of Health from 2006-2012 helping also the Chinese government with Stem Cell legislature.

In 2009 he was appointed first the Global Director for Research and Development for Cell Therapies at GE Healthcare. In 2013 he was appointed Chief Scientist for Cellular Sciences to lead their research for technology development within cellular therapies and diagnostics. He is a member of the Board of Directors of the Canadian Centre for the Commercialisation of Regenerative Medicine (CCRM) and Scientific Advisor for BioLamina. He also serves as the Director of SLM Blue Skies Innovations Ltd, providing expert analysis in emerging healthcare technologies for the life sciences investment community.

Sessions

Linkin

Bio

Harriet  Fear joined One Nucleus (formerly ERBI) as CEO in February 2009. She previously worked as a Diplomat with the British Foreign Office for 21 years serving in over 17 countries around the globe. Half her career was spent in the commercial field, latterly heading UK Trade & Investments national life sciences trade team for over 5 years.

She was attracted to the role at One Nucleus because she wanted to spend time helping companies maximise their competitiveness and to lead a team which already had an excellent reputation. Since her arrival at One Nucleus, the company has redefined its membership (now life science and healthcare, not only biotech), formed strong and strategic relations with like minded US counterparts for the benefit of members and merged ERBI with London Biotechnology Network to enhance the offer to members and create a stronger critical mass on the international stage.

One Nucleus is the largest membership organisation in Europe. A not-for-profit private company, it has over 450 members including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

The One Nucleus mission is to maximise the global competitiveness of its members. For their science and technology-based members, this means being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For their business and professional services members, it means delivering exceptional services that significantly enhance the business performance of their clients.

Harriet Fear has accepted the Prime Ministers invitation to continue in her UK Business Ambassador role for a further two years to 2017. She continues to be Chief Executive of One Nucleus – her first priority and passion. By accepting this invitation, Harriet has agreed to undertake, in the margins of her personal or business travel, a programme of activities developed by and with the Government until July 2017. This could include for example, hosting a reception in a country she is travelling to in order to highlight UK expertise in the life science and healthcare sector, briefing UK Ministers and HM Ambassadors on key business priorities and interests as they might arise; meeting overseas Ministers and inward missions; and providing insights into how UK Trade & Investment can better deliver for business.

Sessions

Linkin

Bio

Vipul Jain is a serial entrepreneur who specialises in spotting business opportunities while they are still in nuance stage. An MBA from Rochester Institute of Technology, Rochester, New York, class of 1999, I started my career by establishing a fabrics import business as an extension of the family business of Garment exports in 1999.

In 2002 I established an animation studio by the name of Mirage Animation which produces television quality animations for clients such as Warner Brothers, Disney, Channel 5 etc.

In 2003, I spotted an opportunity in Medical Tourism sector while the world was still to wake up to the phenomenon. Vipul helped founding a company called PlanetHospital and built it to be the worlds largest medical tourism company. I exited the company in 2011 to establish my own Medical Tourism business by the name of Mirage Medserv focusing on the third world countries, Russia, Africa and Mid East. Mirage is today one of the largest facilitators of patients of almost all major hospitals in the country.

In 2013, I established Advancells, which is a research based company focusing on providing cutting edge Stem Cell Therapies for patients with life threatening diseases also catering to lifestyle diseases and anti aging technology. Advancells is slowly rising to be a leader in a very small space of modern medicine and is in process of filing patents for treatment of multiple diseases.

Sessions

e-mail

Bio

Phil Jackson previously held a range of senior positions within the Canadian healthcare system, as Director of Strategic Support and chief adviser to the Medical Officer of Health for the City of Toronto Health Department, the largest public health department in North America with 15 offices and 1,800 staff. Prior to this Phil led the development and establishment of the Ontario Agency for Health Protection and Promotion, with 14 laboratories and 600 plus staff, serving as the founding Vice President of Strategy and Planning. Phil served as part of the control team for the SARS outbreak in 2003 and the H1N1 outbreak of 2009.

Phil Jackson,As Head of Research to the Expert Panel on SARS, Phil led the drafting of a major two volume expert report into Infectious Disease Control and Emergency Response (the Walker report). Phil had served as the Canadian representative to the OECD working group on New Genetic Technologies and serving as Ontario Director for Health Information and Sciences led the drafting of an internationally acclaimed report on Genetic Testing. Phil has led a wide range of major health system initiatives in his career including leading the complete red-design of Stroke prevention, treatment and rehabilitation services for a population of over 11m people, the implementation of Hospital Report Cards across 134 hospitals, the establishment of 14 Regional Infection Control Networks and multiple other initiatives. Phil is the recipient of several Canadian awards for health reform, most recently the Amethyst Award and Ace Award.

Sessions

Linkin e-mail

Bio

Dr. Anil Wali is currently the MD at Foundation for Innovation and Technology Transfer (FITT) – an autonomous industry interface organization of IIT Delhi. He is managing technologies and driving innovations and enterprise at the academia besides looking at issues of concern to SMEs. He has worked in chemical industry for 19 years before taking up the present position. Besides several publications, patents and reports to his credit, he has a strategic customer and quality orientation, and brings a practical perspective to solving technical problems. He is also called upon to deliberate and participate in the area of clean technology and sustainability. His multifaceted experience towards technology innovation and management, industry partnership, project issues, entrepreneurship, IPR, education, training, etc is sought for advice / association with several committees and programmes. He is an IIT Delhi Doctorate.

Dr. Anil Wali at Foundation for Innovation and Technology Transfer (FITT) believes that FIIT is an industrial interface organization, established at the Indian Institute of Technology Delhi (IIT Delhi) as a Registered Society on 9th July 1992. Dr NC Nigam was the founding Chairman of FITT, and Dr AK Sengupta was the first full-time Managing Director. IIT Delhi’s Review Committee Report -1986, recommended the setting up of an industrial foundation to enhance the programmes of interaction and collaboration between IIT and industry. To implement this recommendation the Institute took up this initiative, with a seed grant received from government at that time, which, led to the setting up of FITT.

FITT aims to be an effective Interface with the Industry to foster, promote and sustain commercialization of Science and Technology in the Institute for mutual benefits. For over twenty years now, FITT has been an interface between the Institute and the industry and has been devising innovative ways to create partnerships and linkages with business and community to enable knowledge transfer for common good. The team at FITT and academicians from IIT Delhi has been largely responsible for the successful outreach efforts including extensive S&T collaborations.

Sessions

Linkin

Bio

Dr Michel Baijot is Head of Cipla Global Vaccines. He is a life science executive bringing over 25 years of experience in building vaccine businesses with significant contribution in strategy, licensing, M&A, technology transfer and finance. His positions with both biotechs and big pharmas (GSK Vaccines, JnJ Crucell) and his concrete achievements in the vaccine marketplace reflect an in-depth knowledge of the vaccine environment in developed and developing countries. In his role of Head of Cipla Global Vaccines, he is leading the Cipla – Serum Institute of India partnership. He has been Chairman of the Belgian Biotech Association.

General/Business Unit Management, Healthcare, Big Pharma and Biotech,In Both Developing and DevelopedCountries,25 Years Worldwide Experience/Network in Vaccines, Mabs and Diagnostics

Sessions

Linkin

Bio

Yvonne Naughton was previously Head of Business Development and New Product Planning in the UK and Ireland for over three years, and before that held several positions at Sanofi in market access opportunities in Paria and Ireland for cardio thrombosis and arrhythmias. Before Sanofi, she was clinical safety officer at Novartis, and worked in drug safety at Quintiles. She has a PhD in Pharmacology from University College Dublin.

Yvonne Naughton was leading the UK and Irish side of our Global External Science & Partnering organisation. Our remit is to collaborate externally with academic institutions, spin-outs, start-ups, biotechs and non for profit organisations, in order to build Sanofi R&D’s early stage pipeline and accelerate the translation of innovation discovered in the UK and Ireland.

A strategic priority for Sanofi is to sustain innovation in R&D. We will increase our annual global R&D investments to €6bn by 2020, with an increased capacity for external innovation.
Our research interests and investment focus fall into 2 categories. 1: Where we would like to sustain our leadership- Diabetes, Cardiovascular Disease and Genetic Rare Diseases. 2: Where we would like to build a competitive position- Immunology, Oncology and Multiple Sclerosis. We will also invest opportunistically in Neurodegeneration/Pain, Infectious Disease and Ophthalmology.

Sessions

Linkin Twitter

Bio

Venkateswarlu Nelabhotla comes with a very rich and global experience of successfully leading organizations in the Life sciences and Consumer Products businesses. He has held top management roles in the life sciences space in companies like Shantha Biotech (A Sanofi Company) and Aurobindo Pharma and he immensely contributed to their all-round growth. Shantha Biotech – a biosimilar and vaccine company, was eventually acquired by Sanofi for around $ 800 MN in 2010. He has been a part of significant revenue growth and significant value creation in Aurobindo Pharma in the global business segment of APIs and finished dosage form products in multiple therapy areas. He has held CEO roles in Emami and Cavinkare, CPG companies, growing them significantly with an all rounded approach. During his stint at Emami (a listed company) as CEO, the company’s market cap went up from $ 300 MN to $ 1.2 BN. The momentum thus created, has made Emami a $ 3.7 BN market cap company now. During early part of his career, he created some very successful brands in Cavinkare, a leading CPG company from India, and built the organization with a 10X revenue increase in 6 years’ time and that early momentum has made Cavinkare one of the established Consumer product companies in India. He comes with core strengths in Strategy, Innovation, Marketing, Organization building, Finance, M&A and Governance. He has been an integral part of many industrial forums in Life sciences and CPG business.

Sessions

Bio

Stephen Shuttleworth joined Karus as CSO in 2008, and is the founding scientist of the company’s PI3K-p110β/δ and HDAC6 programs. Over the last 21 years, he has established a strong track record in R&D management, and in the design and development of molecular-targeted therapeutics for cancer, immune-inflammation and metabolic diseases. Prior to Karus, Stephen held senior positions in UK and North American biotech, notably at Celltech-Chiroscience (UK), BiochemPharma-Shire (Quebec), Tularik-Amgen (California), CRUK, and Piramed (UK) where he directed the PI3K-p110α and p110δ programs, designing and leading the preclinical development of GDC-0941 (Pictilisib), currently in Phase II cancer trials, under the auspices of Roche, who acquired Piramed in 2008 for $175M.

Stephen Shuttleworth has authored over 130 publications and patents, has been an invited speaker at over 40 major international conferences, and is a recognized opinion leader in the PI3K and HDAC arenas. He obtained his BSc and PhD in Chemistry from the University of Liverpool, and was made a Fellow of the Royal Society of Chemistry in 2007.

In 2014, he was appointed Professor and Honorary Chair at the University of Manchester (Faculty of Medical and Human Sciences) in recognition of his work on small molecule drugs to treat chronic human diseases.

Sessions

Linkin

Bio

Dr. S.D. Ravetkar is an Executive Director with Serum Institute of India Ltd. Apart from his Doctorate he holds degrees in Management and Finance. He has authored various research articles in national and international journals. He is also on advisory board of various national and international organizations and journals. He has more than 43 years techno-commercial experience in biotech industry in various areas like QC, production, projects planning & research. At present his major responsibility is manufacturing of Bacterial combination vaccines mainly Pentavalent and Hexavalent vaccine. He has extensively worked on microbial and bioengineering aspects of vaccinology and also has got expertise on technology transfer. He has widely traveled worldwide. He is listed amongst 15 influential figures in the Asian Vaccine Industry.

Dr S D Ravetkar, Executive Director, Serum Institute of India says that the company has put programme in place to achieve the ambitious plan to offer new vaccines

Serum Institute of India Ltd., is the worlds no. 1 producer of Diphtheria, Tetanus, Pertussis, HIB, BCG, Hepatitis B, Measles, Mumps, Rubella vaccines. It is estimated that about 60% of the children in the world receive at least one vaccine manufactured by Serum Institute of India Ltd.

Key focus in the coming year will be enhancing further capacities of above vaccines for which state of art plants are under various stages of completion. The growth has its own problems and challenges. Planned programme has been put in place for handling these issues.

Major thrust is also given on further strengthening quality systems by adding Process Analytical Technology (PAT) in various stages of manufacture of vaccines. More focus is given on incremental innovation than only on disruptive innovation. The technical team building by establishment of new training center is given major thrust.

Serum is also working with various Universities and Research Institutions in country and overseas, in Europe and U.S. to leverage advantage of mutual strengths in knowledge building. The development of critical knowledge mass is thus at center of various activities.

With robust pipeline of various newer vaccines in offing structured programme is carried to reduce time to market. Products on the horizon are many like Rota and Pnemococcus and HPV vaccines. This in itself is a gigantic task of putting new R & D incubators and going through entire process of germination of idea till commercialization.

Innovation is also being implemented in supplying various new vaccine administration systems and for effective measurement thereby validation of cold chain management.

These efforts will help make vaccines available at affordable cost to infant population in world. With acquisition of Bilthoven Biologicals in Netherlands Serum Institute of India Ltd., is looking for entry in Western regulated markets, In years to come as our vaccines are already manufactured in world class environment confirming to International FDA.

Sessions

Linkin

Bio

Sakate Khaitan is the senior partner at Khaitan Legal Associates. Sakate divides his time between London and Mumbai.

Sakate Khaitan heads the corporate M&A, funds, restructuring and insurance practice at Khaitan Legal Associates. Sakate advises clients on inward investments into India and on an array of India-focused cross border transactions. Having started his career in litigation, Sakate has over 11 years of litigation experience advising various clients in their disputes that included high profile joint venture disputes, tax disputes and disputes with regulators. Sakate also serves on the boards of several companies as a non-executive director, lending his legal and business acumen to businesses around the globe. Sakate assists clients with pragmatic and commercially sound advice on dealing with Indian rules and regulations. His clients include multinationals, private equity funds, financial institutions, fund managers, and HNIs.

In his experience that spans over two decades Sakate Khaitan demonstrates a deep commercial understanding of several industry sectors and significant transactional insights that offer immense value to the client.

Sakate Khaitan is the alumnus of London Business School (“LBS”) and is also the co-founder of the India Business Forum (“IBF”) at LBS. The IBF is a platform that was created to build awareness and facilitate discussions on and encourage cross border investments to/from India.

Sakate Khaitan is dual qualified and is a member of the Bar Council of India and is also admitted as a solicitor of the Supreme Court of England and Wales. However, he exclusively practices Indian law.

Sessions

Linkin

Bio

Rahul Garella is Senior Vice President, Head of International Pharmaceuticals at Endo Pharmaceuticals

– Leadership experience with full P&L responsibility for European subsidiaries.

– Top line and EBIDTA targets and overall P&L management and delivery.

– Leadership and strategy to bring differentiated generics and speciality products across Western Europe.

– Business strategy including licensing, building front ends, acquisitions and partnering

– Rich geographical experience in Europe, Asia Pacific and South America

– On the Editorial board of ‘Journal of Generic Medicines’ Past Recognitions/Awards:

– Led Glenmark, UK and achieved recognition for business performance by the London Stock Exchange group through their publication ‘1000 Companies to Inspire Britain’ (www.1000companies.com) in December’13

– Achieved recognition for Glenmark as amongst the fastest growing companies in the UK though a report by the CII (Confederation of Indian Industry) and Grant Thornton in its report ‘India meets Britain’ in March’14‘ Specialties: Business development for Generics (APIs and finished dosages) with companies in Europe, Latin America and Asia Pacific.

Recognition/Awards:

– Led Glenmark, UK and achieved recognition for business performance by the London Stock Exchange group through their publication ‘1000 Companies to Inspire Britain’ (www.1000companies.com) in December’13

– Achieved recognition for Glenmark as among the fastest growing companies in the UK by the CII-Grant Thornton in their report ‘India meets Britain’ in March’14‘

Sessions

Linkin

Bio

Naveraj Gill joined the department in 2002 to complete an EngD in collaboration with HEL Ltd. The project was based on the design and characterisation of an automated miniature bioreactor system for microbial culture. Following this Nav remained in the academic field as a postdoctoral researcher at UCL. She first worked on a large Technology Strategy Board (TSB) grant in collaboration with the Health Protection Agency (HPA) and Syntaxin.

Naveraj Gill research focused on the integration of microscale technology for the rapid development of bioprocesses and design for manufacture of biotherapeutic fusion proteins. She then worked as part of the IMRC in Bioprocessing investigating ultra scale-down microwell-based techniques for studying mammalian cell culture processes for the production of biopharmaceuticals with a view to scale-up to conventional and single-use bioreactor formats. This led to a position with GE Healthcare as a Single-Use Technologies Specialist, which evolved into a wider business development role for upstream technologies covering UK and Ireland. Key responsibilities included designing in single-use technologies, devising strategies for growing the upstream business, consulting on new product developments and managing new product launches.

Naveraj Gill has now returned to UCL as the Strategic Alliance Director to support the department in forging new links with companies and to foster existing relationships, creating a platform for knowledge transfer. She manages the MBI® industrial training programme which has trained over 1,300 individuals from 300 international companies and is the Business lead for the VISION Programme for Senior Executives.

Sessions

Linkin

Bio

Keith Foster, VP of Ipsen bought the biotech and its drug development platform Syntaxin for $37 million upfront with promises of about $170 million more, with most of the money pinned to the fate of a mid-stage therapy for a rare ailment. Dr Foster is a co-founder of Syntaxin, and joined Ipsen to build a botulinum toxin biology platform for new drug development covering a variety of fields. Back in 2010 Ipsen joined a consortium of investors to put $29 million into Syntaxin. The company held a 10% stake in Syntaxin at the time of the buyout.

Sessions

Linkin

Bio

Kay Brickmann is an experienced PhD business development and licensing professional with a significant track record of successful negotiations and completed deals. More than 17 years of post-doctoral experience in the pharmaceutical industry with scientific expertise in the field of cardiovascular R&D evidenced by author-/co-authorship of 15 research papers and 13 patents. Transactional experience with entities in Europe, USA, Japan and China, full understanding of the pharmaceutical drug development process from early discovery to marketing and a fluent German, English and Swedish speaker.

Recently, Kay Brickmann reported ethyl nicotinates as antagonists of the P2Y12 receptor, which is an important target in antiplatelet therapies. A potential liability of these compounds was their generally high in vivo clearance due to ethyl ester hydrolysis. Results: Shape and electrostatic similarity matching was used to select five-membered heterocycles to replace the ethyl ester functionality. The 5-methyl and 5-ethyl-oxazole bioisosteres retained the sub-micromolar potency levels of the parent ethyl esters. Many oxazoles showed a higher CYP450 dependent microsomal metabolism than the corresponding ethyl esters. Structure activity relationship investigations supported by ab initio calculations suggested that a correctly positioned alkyl substituent and a strong hydrogen bond acceptor were necessary structural motifs for binding. In rat pharmacokinetics, the low clearance was retained upon replacement of an ethyl ester with a 5-ethyl-oxazole. Conclusion: The use of shape and electrostatic similarity led to the successful replacement of a metabolically labile ethyl ester functionality with 5-alkyl-oxazole bioisosteres.

Sessions

Linkin

Bio

Karin Conde-Knape is Vice President of Cardiovascular & Metabolic Scientific Innovation at Johnson & Johnson Innovation, London.

Previously, Karin was Global Head of Discovery in the CVM DTA at Roche where she was responsible for all the Early Research efforts as well as the Translational Biomarker and experimental medicine group. While at Roche, Karin was directly or indirectly responsible for identifying and managing numerous external collaborations with well renowned institutions worldwide. In addition, throughout her career at Roche, she had several roles, including laboratory head, project leader, head of pharmacology and co-department head in the CV and Metabolism Disease and Translational Area, both in the US and in Switzerland. She was responsible for setting and implementing the pharmacology strategy for the portfolio in the CVM group in areas such as Diabetes, Atherosclerosis, Dyslipidemia, Kidney, and CV disease.

Karin received her PhD in Nutritional Sciences from the University of Connecticut, and completed her post-doctoral fellowship at Columbia University.

Responsible for identifying, establishing and managing External Scientific opportunities from Early research to Clinical POC in the aread of Cardiovascular and Metabolism.

Sessions

Linkin

Bio

Jonathan  Tobin joined Imperial Innovations in 2011 and specialises in therapeutics and diagnostics investments. He is a board director with antibacterial drug discovery company Auspherix, and diagnostics companies Abingdon Health and Molecular Vision, and a board observer with Cell Medica and Psioxus. Prior to joining Imperial Innovations he worked at MRC Technology, sourcing and evaluating new opportunities for small molecule and antibody drug discovery worldwide. He has a PhD in molecular medicine from UCL, and undertook post-doctoral research at the Cancer Research UK LRI. Jonathan has a First Class degree in Biology from Oxford University and an MBA with Distinction from Imperial College.

Jonathan  Tobin is a life science specialist with experience of early and later stage venture capital deals, specialised in therapeutics and diagnostics. Board director of two specialist diagnostics companies and one drug discovery company, board observer of two biotechs and one molecular diagnostics company.

Drug discovery and business development experience; strong science background (PhD, post-doc, ten publications plus book, and numerous scientific awards and scholarships; MBA with Distinction from Imperial College; First Class degree in Biology from Oxford University.

Jonathan Tobin is a non executive director at artios and Artios is developing inhibitors of DNA Damage Repair enzymes to selectively kill cancer cells through a concept known as ‘synthetic lethality’. This has been demonstrated with the recent success of PARP inhibitors in clinical studies, and the launch of Lynparza™ (olaparib; AstraZeneca). DDR targeted products have the potential to be used in combination with other cancer agents to help prevent cancers from reoccuring.

Artios has in-licensed its lead DDR programme, PolƟ, from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK) and continues to work with CRT and other experts in the field to build its pipeline of novel DDR programmes.

In September 2016, Artios raised a £25m Series A from a syndicate including SV Life Sciences, Arix Bioscience, Imperial Innovations, Merck Ventures, Abbvie Ventures, and Sixth Element Capital.

Sessions

Linkin

Bio

Dr. Kaushik D. Deb, a Heath Care Biotechnology Professional working on developing solutions to unmet medical needs and personalized precision therapies. Developed technology platforms for commercialization and out licensing. Also interested in Rural health care and Clinics. DiponEd is a P4M company (preventive, predictive, participatory and personalized medicine). Merisis Therapeutics – is a fully owned SBU of DiponEd and is involved in the (R&D) development and commercialization of US FDA etc compliant cell processing units, modular clean rooms, BMT / HSCT units, Celluar Therapeutics, Immunotherapies in cancer/ pain/ allergy/ autoimmunity etc, Biologicals, Biosimilars and 3rd Generation Implantable devises and Biomaterials. Also researches in nanobiotechnology, directed stem cell trafficking technologies and integrating Regenerative and Complementary medicine. We work as technology service providers to Corporate Hospitals, Not for profit organizations and Clinics treating Unmet and No-Option medical Conditions.

Dr. Kaushik D. Deb is the founder and director of DiponEd and DiponEd is a P4M company (preventive, predictive, participatory and personalized medicine).

Merisis Therapeutics – is a fully owned SBU of DiponEd and is involved in the (R&D) development and commercialization of US FDA etc compliant cell processing units, modular clean rooms, BMT / HSCT units, Celluar Therapeutics, Immunotherapies in cancer/ pain/ allergy/ autoimmunity etc, Biologicals, Biosimilars and 3rd Generation Implantable devises and Biomaterials. Also researches in nanobiotechnology, directed stem cell trafficking technologies and integrating Regenerative and Complementary medicine. We work as technology service providers to Corporate Hospitals, Not for profit organizations and Clinics treating Unmet and No-Option medical Conditions.

The other activities of DiponEd are related to development of personalized solutions in cell based cosmetics, antiaging, wellness, sports medicine and advanced nanotechnology based FMCG and OTC personal health care products.

Sessions

Linkin

Bio

David Horn Solomon has strong operational and innovation-minded Healthcare Investor, CEO, Board Member, leader, strategic thinker, and decision maker with success- and problem-solving orientation and the ability to assemble strongly motivated high-performance teams. 30 years of experience in the life sciences—biotechnology—pharmaceutical—investing industry in a range of high-level executive positions in various countries.

David Horn Solomon, President and CEO of Bionor Pharma ASA since January 2015, a publically listed healthcare company based in Oslo, Norway, with offices in Copenhagen, Denmark, and New York, NY. From 2008 to 2015 I served as President and CEO of Zealand Pharma A/S, a NASDAQ OMX Company. Before joining Zealand, I held leadership positions at several biotechnology, pharmaceutical and medical device companies. I have extensive experience in pharmacology research, having served as a faculty member at Columbia University’s College of Physicians and Surgeons in New York, NY.

Sessions

Linkin

Bio

Carl Sterritt, with approximately 20 years’ of management and executive level experience in pharmaceutical development and commercialisation in both large and small company settings, Carl has led the Company as its CEO since he co-founded the Group in 2008 together with Dr.Christian Schweiger.

Carl Sterritt held senior management roles at United Therapeutics and Encysive Pharmaceuticals, working on innovative therapies for the treatment of pulmonary arterial hypertension. Carl joined United Therapeutics to establish the company’s European operations in preparation for the marketing approval of Remodulin®, running the subsidiary for six years. In collaboration with physicians in Germany, he was responsible for and holds patents related to United Therapeutics’ decision to develop and commercialise treprostinil; now successfully commercialised in the US as Tyvaso™. Carl was instrumental in the successful commercial launch of Thelin™ and the rapid growth of Encysive’s European operations. Carl founded the Group after Encysive was acquired by Pfizer Inc. for more than $300m.

Since founding Shield Therapeutics plc – a successful and growing specialty pharmaceutical company commercialising novel prescription therapies – Carl has raised close to £70m and led the team that has successfully developed Shield’s two leading assets, Feraccru® and PT20, recently resulting in the approval of Feraccru and completion of Shield’s IPO on the LSE. During this time Shield has also taken PT20 – a treatment for hyperphosphataemia – through a 1st pivotal study, leaving one study to be completed before a marketing authorisation application.

With an under/postgraduate background in life sciences and an MBA from Henley, Carl has approx. 20 years of experience in pharma. Trained in the large pharma environment, he quickly moved into orphan and specialty medicines, working for United Therapeutics as a core member of the Company’s commercialisation team that launched Remodulin® in the USA, after which he established and led the company’s European operations for 6 years. In collaboration with physicians in Germany, he was responsible for and holds patents related to the development and commercialisation of an inhaled form of treprostinil – now commercialised as Tyvaso™. This was followed by a period at Encysive Pharmaceuticals, leading European commercial operations and delivering the successful launch of Thelin™ another treatment for pulmonary arterial hypertension. The company was acquired by Pfizer for over $300m in 2008, following which Carl left, eventually establishing Shield Therapeutics.

A creative, lateral thinker with proven entrepreneurial flair and a clear record of delivering shareholder value. Key strengths include business leadership experience, creation and delivery of effective business strategy, as well as effective communication and relationship building capabilities.

Outside of work Carl enjoys spending time with his family, socialising and participating in or watching a variety of sports.

Sessions

Linkin Google+

Bio

Ajan Reginald is a hugely accomplished and widely recognised expert in the fields of Science and Medicine. Ajan Reginald co-founded Cell Therapy Ltd (CTL) in 2009 with Professor Sir Martin Evans, Nobel Laureate 2007 and CTL is an award winning biotech company developing stem cell therapeutics with clinical programs.

CTL (Cell Therapy Limited) develops cellular medicines to treat life threatening and life altering diseases and is currently focused on CVS indications: Heart Failure and Myocardial infarction. Prior to this Ajan Reginald was Global Head of Emerging Technologies at Roche Pharmaceuticals in which he led efforts to identify and commercialise the best breakthrough life science technologies including a focus on Stem cells. Before Emerging Technologies,

Ajan completed over 30 licensing and acquisition transactions a Business Development Director at Roche. From 2003-2005 Ajan worked with the Boston Consulting Group in the USA & Zurich as a member of both the Life Sciences Practice Area and Intellectual Property Group. Ajan is a Fulbright scholar, a graduate of London Hospital School of Medicine and Dentistry and holds an MBA from the Kellogg Business School at Northwestern University. Ajan enjoys spending time with his wife and young son and in his spare time he plays competitive Hockey, representing England at the over 40’s level.

Ajan Reginald
– Executive Director Cell Therapy Limited (CTL): CTL develops cellular medicines to combat life threatening and life altering diseases.
– Ex-Global Head of Emerging Technologies, Roche
– Ex-Business Development Director, Roche
– Consultant, Boston Consulting Group
– Kellogg School of Management
– Fulbright Scholar
– University of London

Sessions

Bio

Virander Paul joined the Indian Foreign Service in 1991. Prior to his assignment as Deputy High Commissioner of India in London, he was Minister(Press) at the Indian Embassy in Washington D.C. Earlier, he has held diplomatic assignments in Indian Missions in Almaty, Vladivostok, Rome, St. Petersburg and Moscow. At the Ministry of External Affairs Headquarters, he has served in Europe East and Americas Divisions. He served as Director in the Prime Minister’s Office during 2007-2010. He holds a medical degree from All India Institute of Medical Sciences, New Delhi.

The areas of potential collaboration between the UK and India were highlighted during the recent visit of the Indian Prime Minister, Mr. Narendra Modi, to the UK.

The UK has a multiplicity of strengths across sectors and is well placed to engage with the ‘Make in India’ initiative.

Dr. Paul added another development is that Indian individuals states are coming to the UK to collaborate and competing with each other. Already 4 states have come so far such as Rajasthan, West Bengal, Odisha and Andhra Pradesh.

On some of the concerns such as more talk and little results, Dr. Paul explained that is short sighted view. He added during last 15 months alone FDI in India has increased by 29%. India is a big country and it may take some time before results show up.

Dr. Virander Paul finally summed up his thought saying India has come a long way from Red Tape to Red Carpet.

First Secretary, T Ajungla Jamir presented Make in India presentation, the idea of 100 smart city project in India with minimum pollution and max recycling.

Dr. Virander Paul, Deputy high commissioner of India to the UK highlighted that

 “Fundamentals of Indian economy remain strong and Make in India is very popular brand now. Make in India is not a single stand-alone initiative but many additional projects such as Digital India, Industrial corridor also along with it. These initiatives are all interconnected and feed into each other”.

 

Sessions

Linkin

Bio

Rakesh Roshan is a senior member of the management team at Isis. He is a diligent results-driven senior management leader with over 13 years of experience in technology transfer, technology commercialisation, forming and growing new businesses, developing investment strategies and roadmaps, and implementing innovative management policies. Rakesh has extensive accomplishments in motivating and providing strategic guidance to negotiate, execute, and manage complex licence and spinout transactions. He has a strong track record in evaluating, structuring and securing investments for various business propositions that resulted in the formation of a number of technology companies. His proven leadership proficiencies involve directing diverse and cross-functional teams to deliver commercial objectives on time and within budget.

Under his leadership, his team at Isis Innovation has formed more than 15% of all Oxford spin-outs to date and secured equity funding from leading private and institutional investors based in USA, Hong Kong, Japan, China, India and the UK.

His Areas of excellence will be: International Partnerships, New Ventures, Emerging Technologies, Open Innovation Strategy, Technology Roadmap, Investment Decisions, Procuring Investment Pipeline, Due-diligence, Strategic Alliances, Raising Capital, Financial Modelling, Technology Evaluation, Business Development, Business Planning, Contract Negotiations, Business & Risk Analysis, Leadership Skills, Team Management, R&D Management, IP Management, Technology Commercialisation, IP Landscaping and Litigation. .

Sessions